Strategic Growth AI (SGAI) is an operator-led commercialization firm that integrates AI, regulatory strategy, clinical expertise, and technical execution to accelerate payer-backed growth in pharma, biotech, diagnostics, AI-health, medtech, and life sciences.
Every engagement is built on evidence, aligned with reimbursement pathways, and designed for capital-efficient scale.
Track Record
Team Launches
​
Our team has executed end-to-end launches across Rx, devices, diagnostics, digital health, and pharmacy in Canada.
-
Pharmaceuticals
- ​Eusa Pharma launch into Canada for Oncology/Rare Disease full setup
-
​Jazz Pharma, Canadian Entry, Launch and train new staff for Oncology
-
Recordati Pharma Canadian Entry Launch and commercial build for Rare Diseas
-
Takeda Launch Oncology Canadian Launch
-
15 additional Rx launches spanning Oncology, Rare Disease (Orphan), Endocrine (e.g., Thyroid), plus an Adrenaline relaunch.
-
Multiple molecule introductions from Pfizer, Elvium Pharma and Boehringer Ingelheim
​​
-
Diagnostics, Devices & Digital
-
Launched Omega Laboratories full diagnostic suite into Canada and full expansion
-
POCT diagnostics, medical devices, skin-care lines, and AI-enabled solutions.
-
​​
-
Pharmacy & Generics
-
Community/specialty pharmacy channel activation and generics commercialization
-
Ophthalmology & Surgical
-
​​​
-
Experience in surgical/wound-closure supporting ophthalmic use cases.
-
AI SaMD, Digital Health Launch
​
See detailed proof and case studies →
​